Details for Patent: 7,750,028

Title:	Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Abstract:	The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR00001## its use and pharmaceutical preparations comprising this crystal modifications.
Inventor(s):	Portmann; Robert (Pratteln, CH), Hofmeier; Urs C (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee:	Novartis AG (Basel, CH)
Filing Date:	Jan 11, 2006
Application Number:	11/329,945
Claims:	1. A method of treating epilepsy comprising administering to a subject in need of such treatment a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula ##STR00003## characterized by characteristic lines at interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG. and 2.81 .ANG., as determined by means of an X-ray powder pattern. 2. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1 -(2,6-difluorobenzyl )-1H-1,2,3-triazole-4-carboxamide characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 .ANG. (weak), 10.5 .ANG. (medium), 6.6 .ANG. (weak), 5.63 .ANG. (weak), 5.25 .ANG. (weak), 5.14 .ANG. (medium). 4.94 .ANG. (weak), 4.84 .ANG. (very strong), 4.55 .ANG. (strong), 4.42 .ANG. (very weak), 4.34 .ANG. (medium), 4.23 .ANG. (very weak), 4.16 .ANG. (weak), 4.07 .ANG. (medium), 4.01 .ANG. (weak), 3.68 .ANG. (very weak), 3.64 .ANG. (very weak), 3.60 .ANG. (weak), 3.56 .ANG. (weak), 3-51 .ANG. (medium), 3.48 .ANG. (medium), 3.38 .ANG. (very weak), 3.25 .ANG. (strong), 3.19 .ANG. (medium), 3.15 .ANG. (medium), 3.11 .ANG. (weak), 3.07 .ANG. (medium), 2.93 .ANG. (very weak), 2.87 .ANG. (very weak), 2.81 .ANG. (medium), 2.76 .ANG. (weak), 2.73 .ANG. (very weak), 2.68 .ANG. (weak), 2.62 .ANG. (very weak), 2.53 .ANG. (weak), 2,43 .ANG. (weak) and 2.40 .ANG. (very weak). 3. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1 -(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by absorption bands at 3412 cm.sup.-1 and 3092 cm.sup.-1 in the FT-IR spectrum (KBr pellet-transmission method). 4. A method according to claim 3 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-IH-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-IR spectrum (KBr pellet-transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm.sup.-1. 5. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2.6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by an endothermic peak in the range from 230.degree. C. to 260.degree. C., the peak temperature being 239-245.degree. C. and the endothermic signal being 209 J/g .+-.10 J/g. 6. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by an absorption band at 1080 cm.sup.-1 in the FT-Raman spectrum. 7. A method according to claim 6 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-Raman spectrum (powder-reflection method 180.degree.): 3093, 2972, 1628, 1614, 1558, 1466, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm.sup.-1. 8. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2.8-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide in essentially pure form.